Mechanized Enzymatic Determination of Triglycerides in Serum

Bucolo, Giovanni; Yabut, Juanito; Chang, Ting Yen

doi:10.1093/clinchem/21.3.420

Cited by 33 publications

(5 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High‐density lipoprotein (HDL) levels were measured according to the method described by Finley (1978). Trigyceride levels were measured using Stanbio Liquicolor Triglyceride kit according to the method described by Bucolo et al. (1975).…”

Section: Methodsmentioning

confidence: 99%

“…High-density lipoprotein (HDL) levels were measured according to the method described by Finley (1978). Trigyceride levels were measured using Stanbio Liquicolor Triglyceride kit according to the method described by Bucolo et al (1975). LDL level was measured by subtracting both levels of HDL and one-fifth of triglycerides from the levels of total cholesterol (Friedewald et al 1972).…”

Section: Biochemical Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model

Hussein¹,

Ahmed

Hassan

et al. 2006

Int J Experimental Path

View full text Add to dashboard Cite

Obesity and its associated metabolic pathologies are the most common and detrimental diseases, affecting over 50% of the adult population. Our knowledge about the protective effects of melatonin against high-fat diet (HFD)-induced obesity is still marginal. In this investigation, we hypothesized that melatonin can minimize the metabolic pathologies and morphological changes associated with obesity in animals receiving an HFD. To examine these effects, and to test our hypothesis, an animal model formed of male Boscat white rabbits was established. The animals were divided into three groups: (i) a control group fed regular diet; (ii) an obesity group fed an HFD for 12 weeks; and (iii) a treated group fed HFD for 12 weeks and then treated with melatonin for 4 weeks. The animals were killed and their serum and tissues were evaluated for: (i) lipid profile (cholesterol, triglycerides and low-density lipoprotein) and glucose; (ii) antioxidant enzyme (serum glutathione peroxidase, GSH-PX); and (iii) fatty changes (liver, kidney and blood vessels). Compared with the control group, intake of HFD (obesity group) was associated with: (i) a statistically significant increase in blood pressure, heart rate, sympathetic nerve activity, body weight, food consumption, serum lipids, blood glucose levels and atherogenic index; (ii) decreased level of GSH-PX and high-density lipoprotein (HDL); and (iii) fatty changes in the liver and kidney as well as atheromatous changes in the blood vessels. Compared with the obesity group, intake of melatonin (treated group) was associated with: (i) a statistically significant decrease in blood pressure, heart rate, sympathetic nerve activity, body weight, food consumption, serum lipids, blood glucose levels and atherogenic index; (ii) increased level of GSH-PX and HDL; and (iii) disappearance of fatty changes in the liver and kidney as well as atheromatous changes in the blood vessels. The administration of melatonin reduced the metabolic pathologies associated with the intake of HFD, suggesting a protective role. Although the underlying mechanisms are unclear, they may include its antioxidant and receptor-mediated effects. The clinical ramifications of these effects await further investigations.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Biochemical Assaysmentioning

confidence: 99%

Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model

Hussein¹,

Ahmed

Hassan

et al. 2006

Int J Experimental Path

View full text Add to dashboard Cite

show abstract

“…4 The optimal pH for GDH is 10.0, while the Km values for glycerol and NAD + are 1.10 and 0.089 mmol/L, respectively, and the reaction is reversible. 6 For this reason, a simple endpoint assay for TGs using GDH is not a practical strategy. Many research groups have reported assaying TGs using GDH until now.…”

Section: Discussionmentioning

confidence: 99%

“…In these methods, TGs were hydrolysed by lipoprotein lipase (LPL, EC 3.1.3.34) to glycerol and fatty acids, and the substances subsequently derived from glycerol were modified by various dyes and assayed by colorimetric methods (enzymatic colorimetric method). 6,7 Moreover, with the progression of scientific technologies, other assay methods have been reported, including those using chromatography, nuclear magnetic resonance, mass spectrometry and bio-sensors. 8–11 All these methods have a high accuracy and sensitivity; however, because special instruments and trained personnel are required for their execution, the introduction of these methods into the clinical setting has not been smooth.…”

Section: Introductionmentioning

confidence: 99%

A novel assay for triglycerides using glycerol dehydrogenase and a water-soluble formazan dye, WST-8

et al. 2019

View full text Add to dashboard Cite

Background The glycerol-3-phosphate (GPO)-peroxidase (POD) chromogenic method is one of the most widely used methods to assay triglycerides. However, it is well known that peroxidase is affected by reducing agents, and recently, it has been reported that some materials affect its activity. Moreover, there is a high possibility of non-specific reaction, as the method uses many enzymes. Against this background, we developed a simpler assay method for triglycerides without using peroxidase. Methods Triglycerides were hydrolysed to glycerol and fatty acids by lipoprotein lipase followed by the oxidation of glycerol to dihydroxyacetone with simultaneous production of NADH by glycerol dehydrogenase. To overcome incomplete conversion of glycerol to dihydroxyacetone by glycerol dehydrogenase at equilibrium, we added 2-(2-methoxy-4-nitrophenyl)-3–(4-nitrophenyl)-5–(2,4-disulfophenyl)-2 H-tetrazolium monosodium salt (WST-8) to the reaction mixture to remove NADH, allowing the reaction to complete while showing stoichiometric production of reduced WST-8. Results The reaction was linear up to 6.4 mmol/L. The mean intra-assay ( n = 20) and inter-assay ( n = 20) imprecision, as determined by replicate analysis of three pooled human serum samples with different triglyceride concentrations, were 1.1–2.3% and 1.1–1.5% coefficient of variation (%CV), respectively. No interference by 2.5 g/L haemoglobin, 65 μmol/L free bilirubin and 359 μmol/L conjugated bilirubin was observed. The equation obtained in comparison with that by the GPO-POD method including endogenous glycerol-eliminating step was: y = 1.0002x + 0.0395 mmol/L; r = 0.999; Sy/x = 0.049 mmol/L; n = 97. Conclusion Our method is an accurate, yet simpler and more sensitive for the quantitative analysis of triglycerides.

show abstract

“…Lipid testing was performed at the Heinz Nutrition Laboratory at the University of Pittsburgh. [28][29][30] We started by categorizing each man as either receiving or not receiving statin therapy. This was determined by participant self-report at Visit 56.…”

Section: Discussionmentioning

confidence: 99%

Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men

Monroe

Zikusoka

et al. 2015

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

Treating cardiovascular disease (CVD) risk factors, including dyslipidemia, is important in HIV care. Low-density lipoprotein cholesterol (LDL-c) target achievement is a readily available benchmark for dyslipidemia control, although use of this target is not uniformly endorsed by professional societies. We examined whether HIV serostatus is associated with not achieving LDL-c target. Among Multicenter AIDS Cohort Study (MACS) participants completing visit 56 (10/1/2011-3/31/2012), we categorized each man as on or off statin therapy and used NCEP ATP III guidelines to determine if each man was at LDL-c target or not at target. We compared proportions of men not at target and determined predictors using multivariate logistic regression. Sixty of 543 (11.1%) HIV-infected men and 87 of 585 (14.9%) HIV-uninfected men not receiving statin therapy were not at target (p=0.07), while 31 of 230 (13.5%) HIV-infected and 29 of 204 (14.2%) HIV-uninfected men receiving statin therapy were not at target (p=0.82). Factors associated with not being at target (among men not receiving statin therapy) included current smoking (OR=2.31, 95% CI 1.31, 4.06) and a diagnosis of hypertension (OR=4.69, 95% CI 2.68, 8.21). Factors associated with not being at target (among men receiving statin therapy) included current smoking (OR=2.72, 95% CI 1.30, 5.67) and diabetes (OR=5.31, 95% CI 2.47, 11.42). HIV-infected and HIV-uninfected men receiving statin therapy demonstrated similar nonachievement of LDL-c targets. Comorbidities (e.g., diabetes) lowered targets and may explain why goals were less likely to be met.

show abstract

Mechanized Enzymatic Determination of Triglycerides in Serum

Cited by 33 publications

References 1 publication

Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model

Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model

A novel assay for triglycerides using glycerol dehydrogenase and a water-soluble formazan dye, WST-8

Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men

Contact Info

Product

Resources

About